Aura Biosciences 2024 Annual Meeting Proxy Supplement Filed

TL;DR

Aura Biosciences filed proxy supplement for June 20th meeting, no fee.

AI Summary

Aura Biosciences, Inc. is filing a supplemental proxy statement for its 2024 Annual Meeting of Stockholders, scheduled for June 20, 2024. This filing provides additional materials related to the meeting, with no fee required for this submission.

Why It Matters

This filing provides updated information to shareholders regarding the upcoming annual meeting, ensuring they have the latest details for voting on important company matters.

Risk Assessment

Risk Level: low — This is a routine filing of supplemental proxy materials for an annual shareholder meeting, not indicating any unusual company events or risks.

Key Players & Entities

• Aura Biosciences, Inc. (company) — Registrant
• June 20, 2024 (date) — Annual Meeting Date

FAQ

Key Financial Figures

• $585,525 — s Pinos, Ms. Feder and Dr. Hopkins were $585,525, $437,825 and $525,000, respectively.
• $437,825 — s. Feder and Dr. Hopkins were $585,525, $437,825 and $525,000, respectively. 6 Table
• $525,000 — Dr. Hopkins were $585,525, $437,825 and $525,000, respectively. 6 Table of Contents
• $200,000 — Dr. Hopkins received a sign-on bonus of $200,000, subject to repayment as described belo
• $8 — 2021 Plan. (2) Amounts are equal to $8.86, the closing price of our common sto

Filing Documents

• d843877ddefa14a.htm (DEFA14A) — 154KB
• 0001193125-24-161687.txt ( ) — 155KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 5 PRINCIPAL STOCKHOLDERS 11 Table of Contents NON-EMPLOYEE DIRECTOR COMPENSATION The following table presents the total compensation for each person who served as a non-employee member of our Board of Directors and received compensation for such service during fiscal year 2023. Directors who also serve as employees received no additional compensation for their service as directors. During fiscal year 2023, Elisabet de los Pinos, Ph.D., our Chief Executive Officer, was a member of our Board of Directors, as well as an employee, and received no additional compensation for her services as a director. See the section titled 2023 Summary Compensation Table for more information about her compensation in fiscal year 2023. 2023 Director Compensation Table NAME FEES EARNED OR PAID IN CASH ($) OPTION AWARDS ($) (1)(2) TOTAL ($) David Johnson $ 84,000 $ 148,318 $ 232,318 Giovanni Mariggi, Ph.D. (3) Antony Mattessich $ 55,500 $ 148,318 $ 203,818 Rajesh Parekh, Ph.D. $ 40,000 (4) $ 148,318 $ 188,318 Sapna Srivastava, Ph.D. $ 55,000 $ 148,318 $ 203,318 Karan Takhar (5) (1) Amounts represent the aggregate grant date fair value of option awards granted to our directors during our fiscal year ended December 31, 2023, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024. This amount does not correspond to the actual value that may be recognized by the director upon exercise of the applicable award or sale of the underlying shares of stock. Except as noted below, none of our directors held options to purchase our common stock or any other stock awards as

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION Our named executive officers for the year ended December 31, 2023 are: Elisabet de los Pinos, Ph.D., our President and Chief Executive Officer; Julie B. Feder, our Chief Financial Officer; and J. Jill Hopkins, M.D., our Chief Medical Officer and President of Research and Development. 2023 Summary Compensation Table The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years indicated. Year Salary ($) Bonus ($) Stock Awards ($) (1) Option Awards ($) (1) Non-Equity Incentive Plan Compensation ($) (2) All Other Compensation ($) (3) Total ($) Elisabet de los Pinos, Ph.D. 2023 585,525 1,240,688 1,400,963 289,835 19,800 3,536,811 President, Chief Executive Officer and Director 2022 555,000 222,000 18,300 795,300 Julie B. Feder 2023 437,825 496,275 560,385 166,374 1,660,859 Chief Financial Officer J. Jill Hopkins Chief Medical Officer and President of Research and Development 2023 109,375 200,000 (4) 1,210,950 1,365,820 49,536 2,935,681 (1) Amounts represent the aggregate grant date fair value of the restricted stock unit and option awards granted to our named executive officers during the fiscal year ended December 31, 2023, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our consolidated financial statements included in our Annual Report for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024. This amount does not correspond to the actual value that may be recognized by the named executive officer upon exercise of the applicable award or sale of the underlying shares of stock. Amounts for Dr. Hopkins represent initial equity grants she received in connection with her joining the Company on October 16, 2023. (2) Amounts represent the annual bonuses paid with respec